Aptamer-based therapy for fighting biofilm-associated infections

J Control Release. 2024 Mar:367:522-539. doi: 10.1016/j.jconrel.2024.01.061. Epub 2024 Feb 3.

Abstract

Biofilms are key players in the pathogenesis of most of chronic infections associated with host tissue or fluids and indwelling medical devices. These chronic infections are hard to be treated due to the increased biofilms tolerance towards antibiotics in comparison to planktonic (or free living) cells. Despite the advanced understanding of their formation and physiology, biofilms continue to be a challenge and there is no standardized therapeutic approach in clinical practice to eradicate them. Aptamers offer distinctive properties, including excellent affinity, selectivity, stability, making them valuable tools for therapeutic purposes. This review explores the flexibility and designability of aptamers as antibiofilm drugs but, importantly, as targeting tools for diverse drug and delivery systems. It highlights specific examples of application of aptamers in biofilms of diverse species according to different modes of action including inhibition of motility and adhesion, blocking of quorum sensing molecules, and dispersal of biofilm-cells to planktonic state. Moreover, it discusses the limitations and challenges that impaired an increased success of the use of aptamers on biofilm management, as well as the opportunities related to aptamers modifications that can significantly expand their applicability on the biofilm field.

Keywords: Antibiofilm therapy; Aptamers; Biofilm detection; Biofilm disassembly; Biofilm inhibition.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Biofilms*
  • Humans
  • Oligonucleotides
  • Persistent Infection*
  • Quorum Sensing

Substances

  • Anti-Bacterial Agents
  • Oligonucleotides